Meagan Radford
Nurse Practitioner · Stuart, VANPI 1003433590
Payments from drug & device makers
Across 182 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$343
- Novo Nordisk$237
- Otsuka America Pharmaceutical, Inc.$178
- Amgen$172
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$167
- Bayer$166
- plus $2K from 35 others
What the payments were for
- Food & beverage$3,101100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $343 |
| Novo Nordisk | 14 | $237 |
| Otsuka America Pharmaceutical, Inc. | 10 | $178 |
| Amgen | 11 | $172 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $167 |
| Bayer | 7 | $166 |
| AbbVie | 10 | $159 |
| Exact Sciences | 6 | $132 |
| Lilly USA, LLC | 7 | $130 |
| Mylan Specialty L.p. | 6 | $129 |
| Biogen | 10 | $120 |
| Novartis | 5 | $96 |
| Merck | 5 | $75 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $72 |
| Boehringer Ingelheim | 4 | $63 |
| Sanofi | 3 | $62 |
| Nestle Healthcare Nutrition Inc. | 4 | $57 |
| Sanofi-aventis U.S. LLC | 3 | $56 |
| Sunovion Pharmaceuticals Inc. | 3 | $55 |
| Idorsia Pharmaceuticals US Inc | 3 | $50 |
| Vanda Pharmaceuticals Inc. | 2 | $49 |
| Pfizer | 3 | $46 |
| Astellas Pharma US Inc | 3 | $43 |
| GSK | 3 | $42 |
| Lundbeck LLC | 2 | $39 |
| Neurocrine Biosciences, Inc. | 2 | $38 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Johnson & Johnson | 2 | $33 |
| Dexcom, Inc. | 1 | $29 |
| Seqirus USA Inc | 2 | $28 |
| Neurelis, Inc. | 2 | $26 |
| Eisai Inc. | 2 | $26 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Medtronic | 1 | $16 |
| Inogen, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Alkermes, Inc. | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $8 |
How this compares
$3,101 in reported general payments places this provider in the 90th percentile of 2,166 nurse practitioner providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 57 | $82,706 |
| EliquisApixaban | 137 | $54,720 |
| LinzessLinaclotide | 75 | $44,637 |
| FarxigaDapagliflozin Propanediol | 94 | $39,573 |
| JanuviaSitagliptin Phosphate | 68 | $24,351 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 44 | $22,874 |
| Lagevrio (Eua)Molnupiravir | 22 | $20,142 |
| OzempicSemaglutide | 11 | $19,034 |
| CreonLipase/Protease/Amylase | 15 | $18,739 |
| GemtesaVibegron | 56 | $17,301 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $14,673 |
| JardianceEmpagliflozin | 33 | $13,475 |
| DapagliflozinDapagliflozin Propanediol | 44 | $12,720 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 30 | $8,994 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $8,005 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $167 | $82,70657 claims |
| AbbVieLinzess, Creon | $159 | $63,37590 claims |
| PfizerEliquis | $46 | $54,720137 claims |
| MerckJanuvia, Lagevrio (Eua) | $75 | $44,49290 claims |
| AstraZenecaFarxiga | $343 | $39,57394 claims |
| Boehringer IngelheimCombivent Respimat, Jardiance | $63 | $36,35077 claims |
| GSKTrelegy Ellipta, Arexvy | $42 | $23,66756 claims |
| Novo NordiskOzempic | $237 | $19,03411 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $8 | $17,30156 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,166 nurse practitioner providers in Virginia.
Other nurse practitioner in Stuart
- Samantha FoxGate City$207K
- Mikel GrayCharlottesville$174K
- Kevin BrigleRichmond$166K
- Denese GomesRichmond$126K
- Ashley CarmenAlexandria$99K
- Rachel AndersonCharlottesville$90K
- Megan FrancisArlington$81K
- Elizabeth WilletteNorfolk$58K
- Lacey LyleSuffolk$50K
- Sasha LeeVirginia Beach$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.